Novartis (NVS) Pharmaceuticals Canada announced the “successful conclusion” of negotiations with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Pluvicto. “While this is an important milestone, patients do not yet have public access through provincial and territorial formularies. We look forward to timely collaboration with participating jurisdictions to ensure that eligible prostate cancer patients that are urgently awaiting treatment will have access without further delay,” the company stated.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Monte Rosa announces closing of global license agreement with Novartis
- Novartis announces results from updated analysis of Phase 3 trial of Kisqali
- Novartis to hold a virtual investor event
- Novartis says longer-term data for Scemblix ‘reinforce superior efficacy’
- Novartis reports new Phase 3B data for Fabhalta